Immunoengineering the next generation of arthritis therapies

Klimak, Molly; Nims, Robert J.; Pferdehirt, Lara; Collins, Kelsey H.; Harasymowicz, Natalia S.; Oswald, Sara J.; Setton, Lori A.; Guilak, Farshid

doi:10.1016/j.actbio.2021.03.062

Cited by 30 publications

(17 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned before, fibrosis can negatively affect nearly every organ system in the body and is an important factor in disease progression. Target organs for antifibrotic CAR T cell therapy include the heart (hypertrophic cardiomyopathy, coronavirus disease 2019 (COVID-19) myocarditis, ischaemic cardiomyopathies 47 ), the liver (cirrhosis, nonalcoholic steatohepatitis, hepatitis C-induced liver fibrosis, primary biliary cholangitis), lungs (idiopathic pulmonary fibrosis, infectious pulmonary fibrosis including COVID-19), kidneys (diabetic and hypertensive nephropathy, polycystic kidney disease), skin (keloids, wound healing) 53 , joints 54,55 , skeletal muscle (skeletal muscle fibrosis; Duchenne and other muscular dystrophies) and others (strictures, myelofibrosis, radiation-induced fibrosis, sarcoidosis).…”

Section: Future Applicationsmentioning

confidence: 99%

CAR-based therapies: opportunities for immuno-medicine beyond cancer

2022

View full text Add to dashboard Cite

Section: Future Applicationsmentioning

confidence: 99%

CAR-based therapies: opportunities for immuno-medicine beyond cancer

2022

View full text Add to dashboard Cite

“…In recent years, improved understanding of the molecular pathology underlying arthritis has led to the emergence of a number of immunotherapeutic agents that are being investigated to modulate the levels of arthritis-associated inflammatory cytokines, immune cell activity, and inhibiting enzymes [ 133 ]. These are mainly oligonucleotide-based therapeutics such as antisense oligonucleotides (ASOs) targeting specific mRNAs, cytokine inhibitors for inhibiting osteoclast activation, and bone resorption such as TNF-α inhibitors (IFX, etanercept, certolizumab pegol, etc.)…”

Section: Hydrogels As Depot Delivering System For the Treatment Of Ar...mentioning

confidence: 99%

Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) and osteoarthritis (OA) are disabling musculoskeletal disorders that affect joints and cartilage and may lead to bone degeneration. Conventional delivery of anti-arthritic agents is limited due to short intra-articular half-life and toxicities. Innovations in polymer chemistry have led to advancements in hydrogel technology, offering a versatile drug delivery platform exhibiting tissue-like properties with tunable drug loading and high residence time properties This review discusses the advantages and drawbacks of polymeric materials along with their modifications as well as their applications for fabricating hydrogels loaded with therapeutic agents (small molecule drugs, immunotherapeutic agents, and cells). Emphasis is given to the biological potentialities of hydrogel hybrid systems/micro-and nanotechnology-integrated hydrogels as promising tools. Applications for facile tuning of therapeutic drug loading, maintaining long-term release, and consequently improving therapeutic outcome and patient compliance in arthritis are detailed. This review also suggests the advantages, challenges, and future perspectives of hydrogels loaded with anti-arthritic agents with high therapeutic potential that may alter the landscape of currently available arthritis treatment modalities.

show abstract

“…Immunoengineering is a branch of regenerative medicine that focuses on the immune system and that aims to modify the cellular response in order to facilitate tissue reconstruction [ 15 ]. In particular, joint diseases such as OA and RA have been targeted with biomaterials and anti-cytokine treatments as a potential innovative therapy [ 16 ]. Considering the lack of effectiveness of the currently administered anti-inflammatory drugs in both OA and RA, the current task for researchers and clinicians in the musculoskeletal regeneration field, is to develop and implement more effective therapies.…”

Section: Clinical Backgroundmentioning

confidence: 99%

Extracellular Vesicles in Musculoskeletal Regeneration: Modulating the Therapy of the Future

Abreu

Canciani

Raineri

et al. 2021

Cells

View full text Add to dashboard Cite

Tissue regeneration is a hot topic in health sciences, particularly because effective therapies promoting the healing of several cell types are lacking, specifically those of the musculoskeletal system. Mesenchymal Stem/Stromal Cells (MSCs) have been identified as crucial players in bone homeostasis, and are considered a promising therapy for diseases such as osteoarthritis (OA) and Rheumatoid Arthritis (RA). However, some known drawbacks limit their use, particularly ethical issues and immunological rejections. Thus, MSCs byproducts, namely Extracellular Vesicles (EVs), are emerging as potential solutions to overcome some of the issues of the original cells. EVs can be modulated by either cellular preconditioning or vesicle engineering, and thus represent a plastic tool to be implemented in regenerative medicine. Further, the use of biomaterials is important to improve EV delivery and indirectly to modulate their content and secretion. This review aims to connect the dots among MSCs, EVs, and biomaterials, in the context of musculoskeletal diseases.

show abstract

Immunoengineering the next generation of arthritis therapies

Cited by 30 publications

References 149 publications

CAR-based therapies: opportunities for immuno-medicine beyond cancer

CAR-based therapies: opportunities for immuno-medicine beyond cancer

Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis

Extracellular Vesicles in Musculoskeletal Regeneration: Modulating the Therapy of the Future

Contact Info

Product

Resources

About